Search results
Psoriasis study shows high level of arthritis symptoms in patients
Medical Xpress· 5 days agoThe study led by researchers at the Universities of Oxford, University College Dublin and supported...
States struggle to help patients navigate insurance hurdle known as ‘step therapy’
North Dakota Monitor via Yahoo News· 19 hours agoCassidy Yermal, 32, began experiencing debilitating migraines when she was 17 years old. As a...
How AI Is Revolutionizing Drug Development
The New York Times via Yahoo News· 6 days agoMONROVIA, Calif. — The laboratory at Terray Therapeutics is a symphony of miniaturized automation. Robots whir, shuttling tiny tubes of fluids to their...
Why Is My Skin So Itchy?
Verywell Health via Yahoo News· 5 days agoPruritus, or itchy skin, is a characteristic feature of many skin diseases and an unusual sign of some systemic diseases. It can be painful or...
Polycystic Ovarian Syndrome: New Science Offers Old Remedy
Medscape· 6 days agoAn ancient Chinese remedy for malaria could offer new hope to the 10% of reproductive-age women...
Why Diabetes, High Blood Pressure and More Conditions Can Make Heatwaves Dangerous
CNET· 1 day agoA heat wave has stifled parts of the US this week, with people across the Midwest and Northeast...
Drug names: How companies and regulators come up with hundreds of new names every year
Quartz· 4 days agoEverything you need to know about the art and science of drug naming in five minutes or less,...
Putting the brakes on chronic inflammation | Cornell Chronicle
Cornell News Service· 7 days agoThe immune system has many pathways to protect the body from infection, but sometimes an overactive...
In a 'gold rush' for treating bowel disease, AbbVie clears one more stage
Crain s Chicago Business· 4 days agoWith the arrival of biosimilar competition for its blockbuster drug Humira, AbbVie has said much of its sales growth potential lies with these two anti-inflammatories. In April, the North Chicago ...
U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio...
Morningstar· 5 days agoApproval supported by two Phase 3 clinical trials that evaluated SKYRIZI® for the treatment of moderate to severe ulcerative colitis: a 12-week induction study, INSPIRE,1 and a 52-week maintenance study, COMMAND2Data showed that clinical remission,